Form 4: Director Sells RBOT Shares Under 10b5-1 Plan

Vicarious Surgical Director Donald F. Tang sold 2,159 shares of Class A Common Stock in pre-scheduled transactions.

Summary

• Donald F. Tang, a Director and 10% Owner of Vicarious Surgical Inc. (RBOT), reported sales of Class A Common Stock.
• On August 19, 2025, Tang sold 100 shares at a price of $6.68 per share.
• On August 20, 2025, Tang sold an additional 2,059 shares at a price of $6.04 per share.
• These transactions were conducted pursuant to a Rule 10b5-1(c) plan, indicating they were pre-scheduled.
• Following these sales, Tang beneficially owns 43,178 shares of Class A Common Stock.

Sentiment

Score: 5

Explanation: The sales by a director and 10% owner, although pre-planned under a 10b5-1 plan, represent a reduction in insider ownership. The declining price of the sales could also be seen as a minor negative indicator, leading to a neutral to slightly negative sentiment.

Positives

• The transactions were conducted under a Rule 10b5-1(c) plan, which suggests pre-planned sales rather than reactive selling based on new, non-public information.

Negatives

• A director and 10% owner sold a total of 2,159 shares, which could be perceived negatively by investors as it reduces insider ownership.
• The sales occurred at declining prices ($6.68 to $6.04), which might indicate a downward trend in the stock price around the transaction dates.

Industry Context

Insider sales are common, but a director selling shares, even under a 10b5-1 plan, can sometimes be viewed with caution by the market, especially in growth-oriented sectors like medical robotics where insider confidence is often closely watched.

Related Party Transactions

• The reported sales of Class A Common Stock by Donald F. Tang, a Director and 10% Owner, constitute related party transactions.

Stakeholder Impact

• Shareholders may interpret the sales as a reduction in insider confidence, potentially leading to negative sentiment or downward pressure on the stock price.

Key Dates

Recommendation

While the insider sales by a director and 10% owner could be perceived negatively, the fact that they were conducted under a pre-arranged 10b5-1 plan mitigates concerns about reactive selling based on new, non-public information. Without additional context on the company's fundamentals or future prospects, these routine sales do not warrant a strong buy or sell recommendation, suggesting a 'hold' position for existing investors.

Keywords

Vicarious Surgical, RBOT, Form 4, Insider Sale, Director, Stock Sale, 10b5-1 Plan, Medical Robotics, Surgical Technology